Healthcare and Medicine

Bottom Manufacturing Artificial Tender

🏛️ KATHOLIEKE UNIVERSITEIT LEUVEN
📄 Tender ID: 497237303 📅 Published: 21 Nov 2023

📋 Tender Overview

Bottom-Up Manufacturing Of Artificial Anti-Tumor T Cells

T cells play a central role in anti-tumor immune protection. While their ability to target and eliminate emerging tumor cells is increasingly recognized, fully-established tumors can efficiently evade T cell response. Significant efforts spanning several decades of research have been made to develop T cell-based therapies manufactured from donor-derived T cells. The use of tumor-directed T cells engineered to express chimeric antigen receptors (CARs) represents, to date, one of the most successful applications for treatment of chemoresistant cancers. However, several major drawbacks, including economic factors, suboptimal functioning and life-threatening side effects, are still hindering the full potential of T cell-based therapies. To address this issue, we aim to generate Artificial T cells (ArTCell) that will mimic the anti-tumor function of a T cell-based therapy but in a safer, more efficient and less expensive product. ArTCells will incorporate two key features of activated T cells into Giant Unilamellar Vesicles (GUVs): the specificity of tumor cell recognition and the cytotoxic activity achieved through death ligands and cytolytic proteins. Functionalization of the GUVs will be confirmed by immunofluorescent labelling of membrane proteins (i.e. TRAIL, LFA-1 and CAR) and detection with flow cytometry. The morphology of ArTCell will be monitored via cryo-EM, SEM, and confocal microscopy. The ability of ArTCell to target and kill tumour cells will be thoroughly validated in vitro by a combination of functional and high resolution live imaging assays as well as in vivo with two cell line- and patient-xenografts mouse models. The ArTCell could allow to circumvent many of the current technological limitations that hinder a more wide-spread applicability of cell-based therapies, without being subject to tumor-mediated inactivation

Funded Under
The European Innovation Council (Eic)
Total Cost
€ 3 391 796,25
Eu Contribution
€ 3 391 796,25
Coordinated By
Katholieke Universiteit Leuven
Belgium

🔍 Key Information

📄
Tender Reference No.
497237303
📅
Publication Date
21 Nov 2023
💰
Estimated Value
N/A
🌐
Sector
Healthcare and Medicine
📅
Deadline
31 Jan 2029
📝
Notice Type
Projects
📍
Location
Belgium
📑
Contract Duration
5 Years 2 Months 10 Days

📁 Documents & Downloads

View All Documents →
# Document Name Type Action
2
T497237303.html
HTML

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
807
days remaining · 31 Jan 2029
🔔 Set Alert

🧭 Quick Facts

Authority KATHOLIEKE UNIVERSITEIT LEUVEN
Country Belgium
State / UT N/A
Tender Type Project Information
Currency EUR
Similar Tenders
Loading similar tenders…